For research use only. Not for therapeutic Use.
Litronesib (Cat.No:I005426) is a selective, allosteric inhibitor of Eg5, which may result in mitotic disruption, apoptosis and consequently cell death in tumor cells that are actively dividing.
| Catalog Number | I005426 |
| CAS Number | 910634-41-2 |
| Molecular Formula | C23H37N5O4S2 |
| Purity | ≥95% |
| Target | Cytoskeleton |
| Solubility | 10 mM in DMSO |
| Storage | Desiccate at -20C |
| Reference | </br>1:Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer. Infante JR, Patnaik A, Verschraegen CF, Olszanski AJ, Shaheen M, Burris HA, Tolcher AW, Papadopoulos KP, Beeram M, Hynes SM, Leohr J, Lin AB, Li LQ, McGlothlin A, Farrington DL, Westin EH, Cohen RB.Cancer Chemother Pharmacol. 2017 Feb;79(2):315-326. doi: 10.1007/s00280-016-3205-5. Epub 2017 Jan 17. PMID: 28097385 </br>2:A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors. Wakui H, Yamamoto N, Kitazono S, Mizugaki H, Nakamichi S, Fujiwara Y, Nokihara H, Yamada Y, Suzuki K, Kanda H, Akinaga S, Tamura T.Cancer Chemother Pharmacol. 2014 Jul;74(1):15-23. doi: 10.1007/s00280-014-2467-z. Epub 2014 Apr 22. PMID: 24752449 </br>3:Investigation of the mechanism of racemization of litronesib in aqueous solution: unexpected base-catalyzed inversion of a fully substituted carbon chiral center. Baertschi SW, Jansen PJ, Montgomery RM, Smith WK, Draper JR, Myers DP, Houghton PG, Sharp VS, Guisbert AL, Zhuang H, Watkins MA, Stephenson GA, Harris TM.J Pharm Sci. 2014 Sep;103(9):2797-808. doi: 10.1002/jps.23918. Epub 2014 Mar 14. PMID: 24633856 |
